This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/pharmgkb/
n17http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/pubchem-substance/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00469/identifier/chemspider/
n21http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00469
rdf:type
n3:Drug
n3:description
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
n3:group
approved
n3:halfLife
72 hours (range 59 to 74 hours)
n3:indication
For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain.
owl:sameAs
n17:DB00469 n18:DB00469
dcterms:title
Tenoxicam
adms:identifier
n8:46507303 n11:5312154 n12:D01767 n13:4471584 n14:PA131890625 n15:DB00469
n3:mechanismOfAction
The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.
n3:synonym
Ténoxicam Tenoxicamum Tenoxicam
n4:hasAHFSCode
n5:28-08-04-92
n3:proteinBinding
99%
n9:hasConcept
n10:M0102060
n3:IUPAC-Name
n6:271B57AB-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B57B1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B57B0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B57AD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B57AE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B57AF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B57C1-363D-11E5-9242-09173F13E4C5 n6:271B57A9-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B57C3-363D-11E5-9242-09173F13E4C5 n6:271B57A7-363D-11E5-9242-09173F13E4C5 n6:271B57AA-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B57A8-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n21:M01AC02
n3:H-Bond-Acceptor-Count
n6:271B57B7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B57B8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B57B2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B57B3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B57B5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B57B4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B57B6-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59804-37-4
n3:category
n3:containedIn
n19:271B57A6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B57BD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B57BF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B57C0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B57C2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B57BC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B57BB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B57BE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B57AC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B57B9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B57BA-363D-11E5-9242-09173F13E4C5